Is Telehealth Better Used to Treat Patients or Help Other Physicians Treat Patients? An Agent-Based Modeling Study of Healthcare Provision by Chary, Michael
Is Telehealth Better Used to Treat Patients or Help Other Physicians Treat
Patients? An Agent-Based Modeling Study of Healthcare Provision
Michael Chary
Weill Cornell Medical College
mic9189@med.cornell.edu
Abstract
Telehealth, the delivery of medical care remotely,
is hoped to increase access to specialty services
and improve health care utilization. Physicians can
provide telehealth to each other (e.g. specialist to
generalist) or to patients. Specialists often treat
complex patients who can be adequately cared for
only in academic hospitals, suggesting that providing
specialty services via telehealth will reallocate rather
than reduce system utilization. Here I use agent-based
modeling to simulate telehealth’s effects on clinical
outcomes and system utilization in medical toxicology. I
found that toxicologist-physician consultation increased
patient health and decreased cost. Toxicologist-patient
telehealth increased cost and system utilization but did
not improve health. The effects were sensitive to patient
complexity and the clinical efficacy of the toxicologist.
Within the limitations of using simulated data and an
incomplete model, these results suggest that telehealth
is more cost-effective when used to provide toxicologist
access to general physicians than to the public.
1. Introduction
The remote provision of medical care, telehealth,
is hoped to increase access to healthcare, for
example by providing more specialty services such as
neurology or cardiology to remote locations or outside
traditional work hours. Telehealth can be provided
between healthcare providers (physician-physician) or
a healthcare provider and a patient (physician-patient).
Earlier access to specialized care may prevent costly
complications and preserve quality of life. However,
specialists are likely to consider only causes within
their expertise, raising the possibility that the effects of
telehealth depend on whether the service is provided to
a patient or a generalist physician.
Medical toxicology is the medical specialty that
diagnoses and treats the deleterious effects of substances
on the body (e.g. venom from animals, poisonous
plants, exposure to caustic cleaning chemicals, or
drug overdose). Toxicology is unique among medical
specialties because it provides its services primarily via
telehealth and diagnoses can often be made without
specialized equipment, relying primarily on collateral
information and physical exam findings, many of which
can be elicited remotely. Medical toxicology, thus,
provides a unique opportunity to ground a model of the
relative efficacy of different points of healthcare access
in real and relevant data.
Agent-based models (ABMs) have been used
to model complex systems where controlled
experimentation is not feasible. An ABM of the delivery
of toxicologic care provides a unique opportunity to
explore the relative efficacy and cost-effectiveness of
various points of access to care. We chose ABM over
other modeling approaches because the components
of an ABM readily correspond to parts of the real-life
healthcare delivery system.
1.1. System for Delivering Toxicologic Care
The Industrial Revolution and urbanization led to
increased exposure to cleaning agents (e.g. bleach,
ammonia) and workplace chemicals (e.g. leaded
gasoline[1], kerosene[2], asbestos[3]) in toxic amounts.
In 1953, the first US poison control center (PCC) was
established in Chicago, reflecting a growing recognition
that poisonings (e.g. drug overdoses, children getting
into the medicine cabinet or cleaning agents under the
sink, adverse reactions to new therapies) were occurring
and that specialized knowledge was required to diagnose
and treat them[4]. Initially, PCCs were funded by state
governments and private companies and staffed by one
toxicologist who oversaw pharmacists with additional
training in toxicology. After recognizing Poison Control
as a public service and rounds of consolidation, most
PCCs today are funded by state governments and
provide free consultation to physicians and the general
public.
To the public PCCs provide general information





on the safe use of substances and advise when to
seek further medical care, reducing the utilization of
healthcare resources. For example, most ingestions
in young children are emotionally charged events, but
rarely require medical intervention if the substances
and amounts ingested can be verified. To physicians,
PCCs provide consultation for the definitive diagnosis
and treatment of life-threatening poisonings, areas the
general physician is unlikely to be familiar with.
Historically, a central question for the toxicologist
was whether observation in a hospital setting
(Emergency Department, Inpatient Ward, Intensive
Care Unit) provides additional value. Because the
vast majority of poisonings do not require acute
treatment, toxicologists have demonstrated most value
in minimizing the testing and interventions done
on mildly poisoned patients. Patients in whom the
substance and amount are reasonably certainly known
and who have no conditions that deplete physiologic
reserve or alter metabolism may often be safely
observed at home in the company of a friend or
family member. Depending on the nature or amount
of substance ingested, some patients may benefit
from treatment in the Emergency Department without
admission to the hospital. Any person who presents to
an Emergency Department is screened and evaluated
for all likely emergent conditions, often leading to
additional uninformative and costly tests. Most tests to
determine blood concentrations of toxins take days to
weeks to provide results. In severe poisonings, prompt
treatment by a toxicologist may prevent avoid clinical
deterioration, restoring the patient’s health enough to
require admission, but not admission to the Intensive
Care Unit.
As more people live longer and with multiple
chronic illnesses, toxicologist-patient consultation may
be less able to decrease health care utilization. Complex
patients are more likely to need a complete medical
evaluation, which cannot be done over telehealth.
Health care centers (hospitals, nursing homes, long-term
rehabilitation and psychiatric facilities) make up an
increasing portion of the calls to PCCs[5]. The
general public is increasingly turning to the Internet.
Decreasing funding for PCCs further motivates the
search for alternative ways to provide toxicological
care. In tandem, more hospitals have toxicologists
on staff than, before, increasing the feasibility of
toxicologist-physician in-person consultation.
1.2. Approaches to the Economic Analysis of
Healthcare Systems
This section discusses cost-effectiveness and
incremental cost-effectiveness as they relate to the
evaluation of health care systems.
Cost-effectiveness refers to the ratio of the cost of
providing a service to its outcome. Outcome is usually
quantified as the patient’s improvement in quality of life
or life-expectancy. It is typically expressed as QALYs
(quality-adjusted life years), a measure that combines
the gain in longevity and quality of life into a single
number[6, 7]. The incremental cost-effectiveness ratio
(ICER) calculates the ratio of the differences in costs to
differences in outcomes for two interventions.
The national health agency in the United Kingdom
(NICE) and pharmaceutical agencies in America use
QALYs (Qualify-Adjusted Life Year) and ICER when
evaluating different therapeutics and interventions[8,
9, 10]. The median ICER for interventions across
three insurance companies was $12, 500 to $32, 200 per
QALY in 2003 US dollars[11]. In this study payments
were reported as bundles, not itemized. A rule-of-thumb
is that an intervention is cost-effective if it is less than
$50, 000 pre QALY, although the Center for Medicaid
and Medicare does not use any explicit threshold
when setting reimbursement rates[12]. The median
cost-effectiveness of ICU stays is reported to be $4, 100
per QALY, varying from $640 for alcohol intoxication
to $30, 625 for kidney failure[13]. Implementing a
team to optimize antibiotic use (antibiotic stewardship
team), decreased the frequency and duration of systemic
infections in the Intensive Care Unit (ICU), with an
ICER of $2, 637 per QALY[14]. However, ICERs may
not fully capture all changes in costs and depend on
accurately assessing improvement in quality of life.
1.3. Current State of Telehealth
Telehealth began with providing neurology expertise
in caring for strokes to remote areas. It now
also helps patients in remote locations manage
chronic conditions without needing to always come
to a hospital or physician’s office. A substantial
barrier in some specialties to using telehealth is
the difficulty in building trust (e.g. psychiatry) or
performing a physical examination (e.g. surgery).
However, psychiatrist-physician telepsychiatry has
proven useful in assessing imminently life-threatening
conditions, such as suicidality, homicidality, or acute
psychosis. Wearable devices partially offset the
limitations of telehealth physical examination[15].
Insurance companies rarely reimburse for telehealth,
thus favoring uses of telehealth that reduce the costs
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associated with delivering services that are reimbursed.
The ICER associated with telehealth for managing
depression in patients with established depression was
£132, 630[16] and £92,000 for managing chronic
medical conditions (high blood pressure, diabetes,
high cholesterol) in patients who also had access
to office-based care[17]. A telehealth short-term
intervention in addition to primary care but in lieu of
cardiology referral had an ICER of £10, 392[18].
1.4. Prior Work: Cost-Effectiveness of
Toxicological Care
Poison Control Centers, historically, improve health
by reducing unnecessary treatments and tests, which,
in turn, reduces health care system utilization and
costs[19]. A cost-effectiveness analysis of PCCs
reported that toxicologist-physician consultation via
PCCs decreased cost, no matter the poisoning (ICER
$50, 000 to $250, 000)[20]. Another analysis of PCCs
calculated that for approximately $825 per case, PCCs
reduced visits to the Emergency Department by 350,000
visits per year and the number of hospitalizations
by 40,000 per year[21]. An analysis of rural areas
calculated that every 43 calls to a PCC saved 1 hospital
admission to the hospital, worth $8, 000[22].
In-person toxicology consultation reduces duration
of admissions and increases hospital revenue, but its
efficacy varies with the complexity of the poisoning. A
retrospective study of 1, 534 mildly poisoned and 2, 227
severely poisoned patients admitted to one hospital
system in Arizona found that in-person toxicology
consultation decreased length of hospitalization by 0.5
days for mildly poisoned patients and 1 day for severely
poisoned patients; with an increase in 33 lives saved
per 1, 00 and roughly $1, 110 fewer healthcare costs
per patient[23]. Another retrospective study of 123, 000
patients with exposure but not necessarily clinical
manifestations of poisoning found that patients admitted
to a dedicated toxicology service had 0.87 days shorter
length of hospitalization and the hospital received an
average of $1, 800 more per patient encounter[24]. A
comparison of 88 patients before and 88 patients after
starting an in-person toxicology consultation service had
no effect on clinical outcomes[25].
1.5. Prior Work: Agent-Based Modeling
Agent-based models (ABMs) are kinds of finite
dynamical systems that simulate the actions and
interactions of autonomous agents over time. They
have been used to simulate the impact of adding
lanes to a highway on traffic flow, the interdependence
between predator and prey populations, and the
impact of proposed zoning laws on urban traffic flow
and pollution[26]. More recently, they have been
used to model the dependence of the dynamics of
COVID-19 infection to the rate of vaccination or social
distancing[27]. ABMs are typically composed of one or
more types of agents, rules specifying how each agent
evolves and interacts with other agents, and, optionally,
spatial constraints, e.g. when modeling traffic flow
or spatially heterogeneous quantities, like wealth or
rainfall. When the agents interact on a two-dimensional
grid, the simulations resemble cellular automata.
In analyzing healthcare systems, ABMs have been
used to identify the most cost-effective screening
interval for eye complications of diabetes[28], the
influence of geography on recommendations to reduce
risk for cardiovascular disease[29], and the influence
of peer networks in modulating the effectiveness of
interventions to decrease adolescent obesity[30].
1.6. Goals of This Study
The goal of this study was to determine
the cost-effectiveness of each point of access
to toxicological care (toxicologist-physician,
toxicologist-patient via PCC, toxicologist-patient
via telehealth). A secondary goal was to determine the
sensitivity of cost-effectiveness to clinical complexity
and the efficacy of clinical care. It was assumed that
the system for delivering toxicological care aims to
maximize health improvement and minimize resource
use.
2. Methods
We created an agent-based model using the mesa
package in Python[31]. Supporting code, figures, and
documentation are available at the GitHub Repository,
ABM-PCC. The model consists of three mutually
exclusive types of agents: Patients, Physicians, and
Toxicologists (Table 3). In this model the term
Patient includes people at home who self-treat, use
toxicologist-patient telehealth, or call PCC as well as
those presenting to a hospital. Patients become poisoned
and, depending on their willingness, seek care in a
hospital or virtually. Patients who seek care in a hospital
are treated by a Physician and, if the presentation
is severe enough, a Toxicologist whom the Physician
consults. Patients who do not seek care in a hospital try
to treat themselves at home by looking for information
on the Internet, calling Poison Control, or directly
contacting a Toxicologist via telehealth.
The central differences between toxicologist-patient
consultation via PCC and via telehealth is that via
telehealth patients interact with the same toxicologist
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Table 1. Literature sources for parameters.
Variable Value References
Fraction of population with
poisoning
0.1 [32, 33]
With fatal poisoning 0.005 [32, 33, 34, 35]
With nonfatal poisoning, low
clinical complexity









-20 [38, 39, 40]
repeatedly, but PCC consultation is free. Telehealth
consultation costs more but improves health more
than PCC consultation. The greater effectiveness of
telehealth reflects the assumption I made that repeated
interactions or the use of video or wearables would
allow toxicologists to perform a fuller evaluation
via telehealth than PCC. Looking information up on
the Internet is free but sometimes provides harmful
information. This models the effect of inaccurate or
misleading information online as well as the difficulties
inherent in self-diagnosis. Contacting PCC will not
provide harmful information. But, if the patient
cannot fully describe the poisoning, the patient may
be inappropriately referred to a hospital or instructed
to stay home. Inappropriate referral signifies advising
a patient to go to a hospital even if the patient
is unlikely to benefit from medical care, thereby
consuming health care resources with no improvement
in health. Inappropriate keeping at home refers to
advising patients whose illness requires treatment that
can only be accomplished in the hospital to stay at home.
Instructing the person to stay at home risks delaying care
and, possibly, worse health outcomes.
The propensities to access each point of care
or become poisoned are modeled as thresholds over
uniform variables. For each propensity all Patients have
the same threshold. At each step the Patient realizes the
propensity (e.g. calls PCC) if a random number is below
that threshold. All random numbers were chosen by the
built-in random number generator provided in Python
3.9.1 over [0, 1].
Table 1 details the parameters and, when available,
empirical work used to choose specific values. In Table
1, the term value refers to the numerical value used
in the simulation. All fractions are between 0 and 1,
health effect was between −100 and 100. The relative
treatment effect, a ratio, had a lower bound of 1. These
values were used in conjunction with the agent behavior
shown in in Table 3.
2.1. Experimental Design
Each simulation contained 1, 000 Patients, 100
Physicians, and 10 Toxicologists. The results reported
in the Results section show the median result.
Table 2 describes the scenarios investigated. A plus
sign indicates the availability of that line of service and
minus sign, the lack. We chose this factorial design
to explore the effects of different lines of service and
their interactions. Each scenario was run in replicate 10
times. To account for the sensitivity of results to clinical
complexity, each replicate was run 10 times, varying
clinical complexity with each run from 0 to 1 in steps
of 0.1, leading to 10 · 10 = 100 simulation runs.
We simulated clinical complexity as a single
parameter that varied from 0 to 1. Clinical complexity
refers to factors extrinsic to the poisoning. For example,
a snakebite could inject venom that causes extreme
swelling of the limbs and a predisposition to bleed.
These effects could be more dangerous in someone
being treated with blood thinners for another disease
or with a hereditary disposition to bleed easily. It also
refers to the effect of social determinants of health,
logistical issues (e.g. delays in seeking care), or
differences in amounts of substance ingested.
3. Results
Figures 2 to 4 illustrate the relationships between
improvement in health (Figure 2), hospital admissions
(Figure 3), cost (Figure 4) and which points of access
for toxicological service were available.
Figure 2 describes the median increase in health
per patient. Health was quantified as a number
between 0 (death) and 100 (full health), with 50
denoting a critical illness. We considered a mild
poisoning to subtract 20 from a patient’s health.
A severe one subtracted 40. Health increased
when no toxicological care was available because
generalist care was still available and self-treatment
was possible. PCC care provided no benefit beyond
toxicologist-patient consultation via telehealth. Access
to toxicologist-physician consultation was associated
Table 2. Simulation plans. Each column denotes a
simulation plan.(+) denotes presence of factor, (-)
absence. TELE, toxicologist-patient telehealth, TOX,
toxicologist-physician telehealth; PCC,
toxicologist-patient telehealth with no follow-up, i.e.
Poison Control Center
TELE + + + + - - - -
TOX + + - - + + - -
PCC + - + - + - + -
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Figure 1. Interaction Diagram of Agents. PCC,
Poison Control Center. Arrows indicate possible
paths. Bidirectional arrows indicate repeated
interactions.
with the biggest increase in health per patient, even
though only 1% of the population had poisonings severe
enough to use this point of access.
Figure 3 describes the median hospital encounters
per 1, 000 Patients. These encounters decreased
when the only point of access for toxicology care
was toxicologist-physician consultation. This decrease
reflects the lack of toxicologists referring patients
in. Toxicologist-patient telehealth was responsible
for more referrals to hospital than PCC was. This
reflects more accurate recognition of complex or
severe poisonings with toxicologist-telehealth than
PCC. Care via toxicologist-patient telehealth partially
offset the increase in hospital admissions when
toxicologist-physician consultation was not available
(Figure 3).
Figure 4 describes the median cost per
patient. Toxicologist-physician consultation
allowed an approximately 20% reduction in cost
Toxicologist-patient telehealth increased costs,
reflecting how some Patients used telehealth, a paid
service, over PCC. Toxicologist-patient PCC reduced
costs, although by less than telehealth increased them.
The overall cost decreased despite the additional fees of
providing toxicologist-physician consultation because
the consultation reduced length of stay by 2 − 4
timesteps (equated in this analysis with days). At each
timestep, the physician billed 100 to increase health by
10 and the toxicologist billed 150 to increase health by
25, leading to an ICER of 150/25 ⇒ 6. The availability
of PCC did not change cost, as expected, because this is
a free service.
This model assumed that a fraction of the population
would have clinically complex cases and present directly
to the hospital. Figure 5 displays the sensitivity
of changes in health and cost per patient to clinical
complexity. In general, a clinically complex patient
is the more likely to require long hospitalizations
and specialist consultation than a clinically simple
patient. Toxicologist-physician consultation improved
health with no systematic impact on cost (blue circles
compared with orange dots). The presence of any point
of access to toxicological care did not change the shape
of sensitivity function. Both cost and health increased
and then saturated. The saturation of health reflects that
patients were discharged from the hospital when their
health was 90/100 and that severe poisonings subtracted
40 from a Patient’s health. The saturation of cost reflects
the trade-off between shorter length of stay, which
Page 4013
Figure 2. Effect of Point of Access to Toxicological
Care on Health Improvement. Y-axis shows
improvement in health. X-axis shows availability
(plus) or lack (minus) of point of access. TELE,
physician-patient telehealth; TOX, physician-physician
telehealth; PCC, physician-patient telehealth with no
follow-up (i.e. poison control center). Total increase
calculated as the area under the curve, e.g. in the
panels in Figures 5 or 6.
reduced general physician billing, and the increased
billing of the toxicologist-physician consultation.
This model assumed that toxicologists help general
physicians treat complex poisoned patients more
effectively than general physicians could on their
own. Figure 6 displays the sensitivity of cost
to toxicologist efficacy. The x-axis displays the
relative efficacy of the toxicologist to the general
physician. A relative efficacy of 0.5 means that
for every unit health the general physician increases,
the toxicologist increases an additional 0.5 units,
i.e. has less half the relative effectiveness of
the generalist. For both toxicologist-physician (top
panel) and toxicologist-patient telehealth, cost per
patient is a decreasing function of the toxicologist’s
clinical efficacy. The highest cost per patient
occurs when telehealth is not available (but PCC
and toxicologist-physician consultation are) and the
toxicologist is half as effective as the general physician,
prolonging length of stay in the hospital. Figures 2 to 4
used a relative efficacy of 2.5.
Figure 3. Effect of Point of Access to Toxicological
Care on Total Number of Patients Admitted. Axes
same as for Figure 2.
4. Conclusions
The goal of this paper was to understand
whether toxicologists improve health outcomes
more cost-effectively when providing patient- or
physician-facing points of access. A secondary
goal was to determine the sensitivity of this
cost-effectiveness to clinical complexity and efficacy.
I created an agent-based model to capture the effects
of toxicologist-physician consultation via PCC or
telehealth, and toxicologist-physician in-person
consultation. As demonstration of its validity, the
model captures the previously described cost-savings of
toxicological care and PCCs.
The key finding of these simulations is that
(the model’s representation of) toxicologist-physician
interactions increase health and decrease costs, while
toxicologist-patient telehealth had the opposite effect.
Toxicologists and general physicians working together
improved health more than either working alone
could. Recognizing that patients with more complex
poisonings are more likely to seek care in hospital, the
main implication of this work is that the primary way
toxicologists improve health is by improving the care
of complex patients. Toxicology-physician consultation
had no effect on system utilization because the physician
consulted the toxicologist after the patient was being
treated in the hospital.
The results presented here agree with previously
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Figure 4. Effect of Point of Access to Toxicological
Care on Cost. Axes and calculation same as for
Figure 2, except that y-axis is logarithmic here.
reported empiric findings in toxicology and telehealth.
A study of poison centers in Illinois divided patients
into five levels of clinical complexity and found
PCC consultation was associated with nearly $800
increased costs in the least clinically complex patients
but a savings of about $4, 500 in the most clinically
complex patients[41]. Telepsychiatry for patients
with established psychiatric diagnoses was associated
with increased cost and hospitalization as compared
to in-person care[42], and the cost-effectiveness
was dependent on practitioner experience with
telehealth[43].
A criticism of ABMs is that their results depend
on many parameters whose values are not empirically
known and that specific results may strongly depend
on initial conditions [44] These concerns apply to
most investigations of dynamical systems, especially
around bifurcation points. Our approach is mindful of
this pitfall and investigates only general dynamics and
makes no conclusions about specific numerical results.
We assessed the sensitivity of our results to clinical
complexity and the magnitude of improvement in health
that toxicologists bring. Another criticism is that ABMs
do not give reproducible results[45]. The results we
present are the average of 100 runs.
This study is a starting point that demonstrates the
utility of agent-based modeling in understanding the
role of various points of access in healthcare systems.
However, there are limitations to this study that future
Figure 5. Impact of Complexity and Toxicologist
Care on Median Health (top) and Cost (bottom) of
Treated Patients. X-axes show complexity. Y-axes,
health (top) or cost (bottom). Crosses represent
simulations with toxicologist care available, circles, no
toxicological care available. Each cross or dot
represents one simulation.
work can address. The model considered each patient
to have only one medical problem and assumed that
(1) there were no medical errors or side effects from
treatment in the hospital, (2) in-hospital diagnostic
accuracy was perfect, (3) treatment universally effective,
(4) all improvements in health were equal, and (5)
that no toxicologist-physician communication happened
via telehealth. Our analysis of cost-effectiveness is
sensitive to the relative magnitude of treatment effects
of physicians and clinical complexity, although in an
expected and plausible manner. I could find no empirical
data for the absolute or relative values of clinical
complexity. The model focuses on acute poisonings. It
does not consider chronic exposures, as might happen
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Figure 6. Relationship between Clinical Efficacy and
Overall Cost Per Patient for Toxicologist-Physician
(top) and Toxicologist-Patient Telehealth (bottom)
lines of service. Legend indicates presence or absence
of service
in the workplace, in a specific location because of
industrial pollution, or from failing to adjust medication
doses as a patient ages or experiences organ failure. Nor
does the model explicitly consider age, although it is
implicit in the clinical complexity variable. This model
does not differentiate between treatment in the ED,
admission to a general hospital ward, or admission to the
Intensive Care Unit. Toxicologist-patient telehealth may
be cost-effective if it, similar to toxicologist-physician
consultation, decreases the need the for Intensive
Care Unit admissions even if it increases the overall
need for admissions, i.e. capturing people earlier
in their illnesses. Admission to the Intensive Care
Unit is approximately 10 times more expensive than
admission to the general ward, owing to the cost
of increased monitoring, individual nursing care, and
frequent use of life-saving procedures and equipment,
such as mechanical ventilation. Indeed, ICU is more
cost-effective for the most critically (yet not fatally)
ill patients [46], suggesting that preventing admission
to the ICU for cases that can be adequately treated
on the floor with a toxicological consultation would
be cost-saving. Using telehealth to provide physician
coverage to ICUs in remote locations (often only staffed
by nurses and physician assistants) was associated with
an ICER of $25, 392 (2014 USD), driven by preventing
transferring the 40% most critically ill patients between
ICUs.
Limitations not withstanding, these results
provisionally suggest that for acute poisonings the
largest and most cost-effective improvements in health
come from toxicologist-physician consultation for
complex patients and that telehealth would be more
appropriately used to extent generalist access to
toxicologists rather than increasing direct patient access
to toxicologists.
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